Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Discussion session - Translational research 2

4144 - Genomic profile and T cell receptor repertoire of lung adenosquamous carcinomas

Date

21 Oct 2018

Session

Poster Discussion session - Translational research 2

Topics

Tumour Immunology;  Cancer Biology

Tumour Site

Presenters

Gen Lin

Citation

Annals of Oncology (2018) 29 (suppl_8): viii649-viii669. 10.1093/annonc/mdy303

Authors

G. Lin1, C. Li2, W. Fang3, W. Chen4, C. Huang1

Author affiliations

  • 1 Department Of Thoracic Oncology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 2 Department Of Pathology, Fujian Cancer Hospital, 350014 - Fuzhou/CN
  • 3 Department Of Medical Oncology, Fuzhou General Hospital, 350014 - Fuzhou/CN
  • 4 Clinical Genetics, Geneplus-Beijing Institute, 350014 - Fuzhou/CN
More

Resources

Abstract 4144

Background

Lung adenosquamous carcinomas (ASC) are morphologically mixed tumors that contain adenocarcinomas component (ACC) and squamous cell carcinomas component (SCCC). However, the genomic profile and immune microenvironment of each component remain unclear.

Methods

ACC and SCCC in ASC (n = 25) were validated by immunohistochemistry and obtained separately by means of laser capture microdissection. Gene panel and T cell receptor (TCR) repertoire sequencing were performed in both components. 578 adenocarcinomas (AC) and 82 squamous cell carcinomas (SCC) were also included for comparison with ASC.

Results

Of 19 paired samples, two components in 94.7% cases had identical gene mutations. The most frequency mutated genes in trunk were EGFR (77.2%), TP53 (44.4%), MDM2 (16.7%), BRD4 (11.1%), CDK4 (11.1%), ERBB2 (11.1%), FAT1 (11.1%) and SMARCA4 (11.1%). Interestingly, the genomic profiles were different when comparing ACC with SCCC, ACC with AC and SCCC with SCC, respectively. MAP3K1 (15% vs. 4.6%) and NF1(15% vs. 4.6%) mutated more frequent in ACC (n = 20) when compared with SCCC (n = 22), while ARAF (13.6% vs. 0%), KEAP1 (13.6% vs. 0%), ALK (13.6% vs. 5%) and PIK3CA (13.6% vs. 5%) in SCCC when compared with ACC. KRAS (11.1%) and APC (7.1%) were observed in AC samples (n = 578), but not in ACC. CDKN2A (24.4%) was exclusive in SCC samples (n = 82) but not in SCCC. Moreover, mutation frequency of EGFR was much higher in SCCC compared with SCC (68.2% vs. 20.7%). The TCR repertoire of two components were markedly different from each other, 57.1% (12/21) paired samples exhibited extremely low level in Morisita-Horn overlap (range from 0 -0.194, mean: 0.09). In addition, TCR clonotype was found in a strong positive correlation with CA125 (p = 0.017, r = 0.70, n = 11) in ACC and with NSE (p = 0.006, r = 0.80, n = 10) in SCCC, respectively.

Conclusions

Our data support the hypothesis that ACC and SCCC in ASC come from the same origin. Diverse genomic profile were exhibited between ACC and SCCC, AC and ACC and SCC and SCCC, which indicated ASC was an unique pathological subtype. TCR repertoire is also distinct in two components in line with the results of genomic profile. Limited by a small number of samples, our study is still ongoing for validation these findings.

Clinical trial identification

Legal entity responsible for the study

Fujian Cancer Hospital.

Funding

Fujian Provincial health systemic youth backbone training projects [grant number 2015-ZQN-ZD-9].

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.